A registered PHASE3 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 3
- Study design
- RANDOMIZED · PARALLEL · SUPPORTIVE CARE · SINGLE
- Evidence population
- Human clinical study registration
- Participants
- 650
- Population
- ALL · 50 Years
- Duration
- 2013-12-17 to 2015-11-19
- Intervention
- Ranibizumab 0.5mg
- Comparator
- Group I ranibizumab 0.5 mg monthly; Group II ranibizumab 0.5 mg TER
- Outcomes measured
- Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 12 — Baseline to month 12; Number of Visits Scheduled — From Month1 to Month 11; Change in BCVA From Baseline to Month 12 — Baseline to Month 12; Average BCVA Change From Baseline to Month 12 — Baseline and every month for 12 months; Mean Change in Visual Acuity BCVA (Letters) From Baseline to Month 12 — Baseline and every month for 12 months; Number of Patients With a BCVA Improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 Letters From Baseline to Month 12 — Baseline an…; Number of Patients With Best Corrected Visual Acuity (BCVA) Loss <5, <10, and <15 Letters by Visit — Baseline and every…; Number of Patients With a BCVA Value of ≥ 73 Letters (Approximate 20/40 Snellen Chart Equivalent) at Month 12 — Baselin…; The Mean Number of Treatment Frequency — Month 12; The Average Number of Days Between Injections — Month 12; Percentage of Participants With Fluid Free Macula Over Time up to Month 12 — Month 12; Change in Central Subfield Retinal Thickness (CSFT) Over Time — Month 12; Percentage of Patients With Choroidal Neovascularization (CNV) Leakage Assessed by Fluorescein Angiography (FA) in the…; Change From Baseline in Composite Score of the National Eye Institute-Visual Function Questionnaire-25 (NEI-VFQ-25) — B…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Summary supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.